CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques

Vaccine
Dennis M KlinmanB Ivins

Abstract

Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants, improving the immune response elicited by co-administered vaccines. Combining CpG ODN with anthrax vaccine adsorbed (AVA, the licensed human vaccine) increased the speed, magnitude and avidity of the resultant anti-anthrax response. The protective activity of these Abs was established by passive transfer to anthrax-challenged mice. The ability of CpG ODN to accelerate and magnify the immune response to AVA suggests this strategy may contribute to the development of prophylactic and therapeutic vaccines against biothreat pathogens.

References

Apr 6, 1995·Nature·A M KriegD M Klinman
Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·D M KlinmanA M Krieg
Sep 1, 1996·The Journal of Laboratory and Clinical Medicine·R F BrandaJ J McCormack
Mar 25, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G J CozonF Peyron
May 21, 1998·Antisense & Nucleic Acid Drug Development·D M Klinman
Dec 22, 1998·The Journal of Experimental Medicine·S SunJ Sprent
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·C L Brazolot MillanH L Davis
Dec 14, 1999·Microbes and Infection·S F Little, B E Ivins
Dec 29, 2000·Nature·H HemmiS Akira
Dec 1, 2001·Nature Medicine·H C LaneA S Fauci
Dec 12, 2001·Vaccine·P R PittmanA M Friedlander
Apr 3, 2002·Canadian Journal of Public Health = Revue Canadienne De Santé Publique·Murray McQuigge
Jul 11, 2002·Microbes and Infection·Dennis M KlinmanMayda Gursel
Jul 5, 2003·Journal of Immunotherapy·Cynthia A LeiferDennis M Klinman

❮ Previous
Next ❯

Citations

Apr 24, 2008·Journal of Leukocyte Biology·Dennis KlinmanSven Klaschik
Sep 1, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Stephen F Little
Jan 25, 2005·The Pediatric Infectious Disease Journal·Stanley A Plotkin
Feb 11, 2011·Current Infectious Disease Reports·Sarah C Higgins, Kingston H G Mills
Mar 9, 2007·Nature Biotechnology·Arthur M Krieg
Mar 26, 2008·Immunology and Cell Biology·Dawn M Jelley-GibbsSusan L Swain
Jul 11, 2007·Current Opinion in Otolaryngology & Head and Neck Surgery·Deidra A Blanks
Aug 29, 2013·Immunopharmacology and Immunotoxicology·Anju ManujaRaj Kumar Singh
Aug 10, 2012·Expert Review of Vaccines·Rebecca Ingram, Les Baillie
Apr 22, 2011·Expert Review of Vaccines·Christian BodeDennis M Klinman
Sep 23, 2009·Expert Opinion on Biological Therapy·Dennis M KlinmanKoji Tomaru
Oct 20, 2009·Vaccine·Arthur M Friedlander, Stephen F Little
Sep 5, 2009·Molecular Aspects of Medicine·Robert J CybulskiAlison D O'Brien
Mar 11, 2009·Advanced Drug Delivery Reviews·Dennis M KlinmanDebbie Tross
Dec 15, 2015·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Dennis M KlinmanTakeshi Shimosato
Oct 7, 2008·Vaccine·Amit LahiriDipshikha Chakravortty
Oct 5, 2007·Microbes and Infection·Dennis M KlinmanTod Merkel
Jul 4, 2006·Clinics in Laboratory Medicine·Florence M Rollwagen
Dec 6, 2006·Annals of the New York Academy of Sciences·Dennis M KlinmanBruce E Ivins
Jan 5, 2011·Immunological Reviews·Theodor ChitlaruAvigdor Shafferman
Mar 20, 2010·Cellular Immunology·Deborah M Brown
Jun 7, 2005·Advanced Drug Delivery Reviews·Robert N Brey
Aug 18, 2010·Vaccine·Folkert SteinhagenDennis M Klinman
Apr 20, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martina KosikovaHang Xie
Apr 2, 2004·Nature Reviews. Immunology·Dennis M Klinman
Dec 7, 2013·Expert Review of Vaccines·Hidekazu Shirota, Dennis M Klinman
Oct 9, 2019·Infection and Immunity·Neslihan KayrakliogluDennis M Klinman
Jul 6, 2004·Immunological Reviews·Dennis M KlinmanDaniela Verthelyi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.